Overview

TMC114-TiDP3-C181: Study to Assess the Pharmacokinetics of Darunavir (DRV) With Different Doses of Ritonavir in Healthy Volunteers.

Status:
Completed

Trial end date:
2008-12-01

Target enrollment:

Participant gender:

Summary

The objectives are to determine the effect of different ritonavir doses on darunavir (DRV) oral exposure following once-daily oral dosing of DRV/rtv for 7 days, in order to establish an optimal ritonavir boosting dose for DRV and to evaluate short-term safety and tolerability.

Phase:

Phase 1

Details

Lead Sponsor:

Tibotec Pharmaceuticals, Ireland

Treatments:

Darunavir
Ritonavir